Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients

Description

Determine the levels of Donor-derived (dd)cell-free DNA(cfDNA )in liver transplant recipients with normal liver function tests (LFTs) indicating stable immunosuppression status (IS). Based on this range use the dd-cfDNA levels to determine over or under IS in liver transplant patients to make changes to their IS medication regimen.

Conditions

Liver Transplant Failure

Talk to us

Study Overview

On this page

Study Details

Study overview

Determine the levels of Donor-derived (dd)cell-free DNA(cfDNA )in liver transplant recipients with normal liver function tests (LFTs) indicating stable immunosuppression status (IS). Based on this range use the dd-cfDNA levels to determine over or under IS in liver transplant patients to make changes to their IS medication regimen.

Retrospective Exploratory Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients

Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients

Condition
Liver Transplant Failure
Intervention / Treatment

-

Contacts and Locations

Dallas

Methodist Dallas Medical Center, Dallas, Texas, United States, 75203

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age: ≥18 years
  • 2. The patient underwent a liver transplant.
  • 3. The patient at least has one level of dd-cfDNA documented
  • * Patient not meeting the inclusion criteria will be excluded.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Methodist Health System,

Parvez Mantry, MD, PRINCIPAL_INVESTIGATOR, Methodist Midlothian Medical Center

Study Record Dates

2024-12-31